Tamsulosin

Evidence Level: L5

Predicted Indications: 10

Tamsulosin

Pharmacist Assessment Report

Tamsulosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Tamsulosin is an alpha-1 adrenergic receptor antagonist originally used to treat benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but there are currently 0 clinical trials and 0 supporting publications for this indication. The prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Benign prostatic hyperplasia
Predicted New Indication	Ambras type hypertrichosis universalis congenita
TxGNN Prediction Score	1.0000
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Tamsulosin is an alpha-1A/1D adrenergic receptor antagonist. It relaxes smooth muscle in the prostate and bladder neck, which eases urinary symptoms in BPH. Detailed mechanism of action data was not available in the data compiled for this report, so this description draws on general pharmacological knowledge.

Ambras syndrome is a rare genetic disorder of hair development, linked to chromosomal rearrangements that affect regulation of the TRPS1 gene. The review found no plausible link between alpha-1 blockade and this underlying genetic pathology. BPH (a urological condition) and congenital hypertrichosis (a hair development disorder) share no clear biological pathway.

The very high score (1.0000) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related hair-related diseases, not biological evidence or a pharmacological rationale. Other top-ranked predictions are also hair-related or developmental conditions (hypertrichosis, hair shaft abnormalities, hypotrichosis, alopecia) and are likewise unsupported by evidence. This clustering suggests a systematic pattern in the model rather than a real signal for tamsulosin.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the top-ranked indication.

For the lower-ranked prediction of alopecia (rank 9), two publications were retrieved, but neither supports tamsulosin use:

33175100 (2021, JAMA Dermatology) concerns suicidality and psychological adverse events with finasteride, a different drug.
32826647 (2021, Cornea) concerns meibomian gland changes in men with BPH and is unrelated to hair loss.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 14200J	Flomaxtra	Tablet 400 micrograms (prolonged release)	Not listed in the data compiled for this report

The only registered route of administration is oral.

Safety Considerations

Product Information (PI) warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.

Contraindications and cautions from the knowledge graph (not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, liver disease, gallbladder disease, priapism, and intraoperative floppy iris syndrome.

Drug interactions: 100 interactions were identified. The main ones from the entries reviewed are:

Major: clarithromycin
Moderate: bupropion, aprepitant, morphine (including liposomal), lorcaserin, cimetidine, clotrimazole, miconazole, dronabinol, nabilone, opium, eliglustat, fenfluramine, dexfenfluramine, glycerol phenylbutyrate, and the SGLT2 inhibitors canagliflozin, dapagliflozin, empagliflozin and ertugliflozin

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is computational only (Evidence Level L5). No clinical trials or relevant publications exist, and no plausible mechanism links alpha-1 blockade to Ambras syndrome. The same applies to the other nine top-ranked predictions, none of which has supporting evidence.

To proceed, the following is needed:

Mechanism of action data to allow a proper mechanistic analysis
A credible biological rationale linking alpha-1 adrenergic antagonism to the predicted condition (for example, preclinical or in vitro evidence)
TGA Product Information (PI) warnings, contraindications and approved indication text, as the current safety data is incomplete
Registered trials or published case reports for any predicted indication before reconsidering
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.